Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Inclusion Criteria: 1. Histologically confirmed Non-GCB DLBCL with extrinsic involvement； 2. Measurable disease of at least 15mm(node)/10mm（extranodal）； 3. ECOG performance status 0-2； 4. Adequate organ function:Cardiac ejection fraction (EF) ≥ 50%;Creatinine clearance rate (≥30 mL/min) of serum creatinine; Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) ≤3 times ULN； 5. Adequate bone marrow function:Platelet count (≥ 50×10\^9/L);Hemoglobin (≥ 8 g/dL);The absolute value of neutrophils (≥1.0×10\^9/L) 6. Estimated survival time ≥3 months 7. Subjects of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study until the follow-up period of the study. Exclusion Criteria: 1. Accepted major surgery within 4 weeks before treatment; 2. Diagnosis of primary mediastinal lymphoma or primary CNS lymphoma; 3. Previous history of indolent lymphoma; 4. Prior malignancy (other than DLBCL), except for cured malignant tumors with no active lesions for 3 years;Adequate treatment of inactive lesions in non-melanoma skin cancer 、malignant tonsilloma or carcinoma in situ; 5. History of intracranial haemorrhage in preceding 6 months,requires or receiving anticoagulation with warfarin or equivalent antagonists; 6. Requires treatment with a strong/medium CYP3A inducer; 7. The previous use of anthracycline-based drugs \> 150 mg/m2; 8. Evidence of complications or medical conditions, including but not limited, that may interfere the conduct of the study or place the patient at serious risk:significant cardiovascular disease(class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification、myocardial infarction within 6 months of screening、uncontrolled or symptomatic arrhythmias) and/or significant lung disease; 9. HIV infection and/or active hepatitis B or active hepatitis C; 10. Uncontrolled systemic infection; 11. Pregnant or breasting-feeding women; 12. According to the researchers' judgment, patients' underlying condition may increase their risk of receiving research drug treatment, or confuse their judgment on toxic reactions.